These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1724922)

  • 21. Comparison of transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen with that into the peritoneal cavity in rats.
    Arimori K; Hashimoto Y; Nakano M
    Chem Pharm Bull (Tokyo); 1990 Jul; 38(7):2050-2. PubMed ID: 1702691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study.
    Lessard E; Fortin A; Coquet A; Bélanger PM; Hamelin BA; Turgeon J
    J Chromatogr Sci; 1998 Jan; 36(1):49-54. PubMed ID: 9443381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations.
    Bauer LA; Black D; Gensler A; Sprinkle J
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):213-6. PubMed ID: 2472362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances.
    Bauer LA; Black DJ; Lill JS; Garrison J; Raisys VA; Hooton TM
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1649-51. PubMed ID: 15793163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity.
    Low CL; Phelps KR; Bailie GR
    Nephrol Dial Transplant; 1996 May; 11(5):881-4. PubMed ID: 8671917
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
    Koup JR; Abel RB; Smithers JA; Eldon MA; de Vries TM
    Ther Drug Monit; 1998 Feb; 20(1):73-7. PubMed ID: 9485559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aging and renal clearance of procainamide and acetylprocainamide.
    Reidenberg MM; Camacho M; Kluger J; Drayer DE
    Clin Pharmacol Ther; 1980 Dec; 28(6):732-5. PubMed ID: 6160015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.
    Jung D; Nanavaty M; Prasad P
    Drug Metab Dispos; 1985; 13(3):359-63. PubMed ID: 2410212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [High performance liquid chromatographic method for determination of procainamide and its active metabolites, N-acetylprocainamide in serum].
    Zhang SQ; Olugo-Edege GC; Zhu YP; Mao FF; An DK
    Yao Xue Xue Bao; 1988 Jun; 23(6):430-4. PubMed ID: 2463733
    [No Abstract]   [Full Text] [Related]  

  • 31. The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration.
    Ellis EJ; Ravis WR; Malloy M; Duran SH; Smyth BG
    J Vet Pharmacol Ther; 1994 Aug; 17(4):265-70. PubMed ID: 7525982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-Acetyl-procainamide kinetics in the elderly.
    Galeazzi RL; Omar-Amberg C; Karlaganis G
    Clin Pharmacol Ther; 1981 Apr; 29(4):440-6. PubMed ID: 6162598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Verification of therapeutic levels of procainamide and N-acetyl- procainamide in ventricular arrhythmia].
    Sinkiewicz W; Marzec A; Jankowski A; Hoffmann A; Makuch K; Romański B
    Pol Tyg Lek; 1990 Jun 4-11; 45(23-24):458-60. PubMed ID: 1703654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capacity-limited elimination of procainamide in man.
    Tilstone WJ; Lawson DH
    Res Commun Chem Pathol Pharmacol; 1978 Aug; 21(2):343-6. PubMed ID: 694230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide.
    Eddington ND; Adekoya F; Kharidia J
    Biopharm Drug Dispos; 1998 Jul; 19(5):291-6. PubMed ID: 9673780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis.
    Sica DA; Yonce C; Small R; Cefali E; Harford A; Poynor W
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):59-64. PubMed ID: 2457560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of slow-release procainamide.
    Tilstone WJ; Lawson DH; Campbell W; Hutton I; Lawrie TD
    Eur J Clin Pharmacol; 1978 Dec; 14(4):261-5. PubMed ID: 729620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concentration-dependent clearance of procainamide in normal subjects.
    Coyle JD; Boudoulas H; Mackichan JJ; Lima JJ
    Biopharm Drug Dispos; 1985; 6(2):159-65. PubMed ID: 2408690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Theoretical basis for interest in acetylprocainamide and clinical experiences with this new antiarrhythmic agent.
    Drayer D; Kluger J; Reidenberg M; Lahita R
    Drug Metab Rev; 1979; 10(2):239-46. PubMed ID: 95247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.
    Lima JJ; Conti DR; Goldfarb AL; Tilstone WJ; Golden LH; Jusko WJ
    J Pharmacokinet Biopharm; 1979 Feb; 7(1):69-85. PubMed ID: 458558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.